Purpose of Review: Storage mite allergy is a relevant differential diagnosis in perennial allergic disease and frequently causes occupational allergy in exposed individuals. However, storage mites are often underdiagnosed due to the similarity of reported symptoms to house dust mite allergy. The purpose of this review is to provide an overview of the latest developments with a focus on allergen-immunotherapy (AIT) for the underestimated epidemic of SM allergy. Recent Findings: Storage mites continue to be a relevant factor for occupational allergy, for example in bakers and farmers. Reported sensitization frequencies vary widely depending on the geographical location. A shift from storage mite as an allergen relevant to rural areas only towards frequent urban sensitization is taking place. Lack of testing for storage mite allergy owes to missing test and therapeutic substances, as well as lack of consciousness. No recent advances in storage mite AIT can be reported, but recommendations on the standardized testing of storage mite allergy were made. The latest development lies in biologics as an alternative, non-disease-modifying therapy. Summary: Standardized testing for storage mite sensitization should be performed. AIT for storage mites has to be performed separately and independently of AIT for house dust mites. Lack of available test and therapy substances as well as limited number of patients in controlled trials needs to be addressed in the future.